E.R. Squibb & Sons, L.L.C.
$251.5M 236,558 recipients
Compare payment profiles
CMS Open Payments · Program Year 2024
GlaxoSmithKline, LLC.
GlaxoSmithKline, LLC. reported $242,144,381.40 across General Payments, Research, and Ownership to 341,439 physicians and teaching hospitals across 361,110 transactions.
- $242.1M
- All-tracks total
- 361,110
- Transactions
- 341,439
- Recipients
- −$9.0M
- General Payments vs PY2023
GlaxoSmithKline, LLC. reported $242,144,381.40 across all CMS Open Payments tracks (General + Research + Ownership) to 341,439 physicians and teaching hospitals in Program Year 2024 - ranking #13 of 1,925 reporting manufacturers (1.7% of the all-tracks industry total); General Payments alone were $26,443,627.44, averaging $709.19 per recipient.
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer glaxosmithkline-llc GlaxoSmithKline, LLC.
$242.1M · #13/1,925 · 1.7% industry · PY2024
- TOT $242.1M
- RANK #13
- SHARE 1.7%
- TXN 361,110
- RCP 341,439
- CAT 8
- GEN $26.4M
- ΔGEN −$9.0M
- TOP1 1.5%
- PY 2024
Volume peers
Nearest volume peer: E.R. Squibb & Sons, L.L.C. ($251.5M)
GlaxoSmithKline, LLC. sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
Release-over-release change
General Payments changed from PY2023 to PY2024
GlaxoSmithKline, LLC.'s CMS-reported General Payments decreased by $9.0M (−25.3%) from PY2023 to PY2024.
How this year-over-year comparison is scoped
The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.
CMS source labels for this exact identifier: PY2022: GLAXOSMITHKLINE, LLC.PY2023: GLAXOSMITHKLINE, LLC.PY2024: GlaxoSmithKline, LLC.. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.
Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.
General Payments: PY2023 vs PY2024
Annual CMS-reported totals for this company, not an all-category Open Payments total
- PY2023
- $35,405,444.09
- PY2024
- $26,443,627.44
What the Data Shows for GlaxoSmithKline, LLC.
Averaging $670.56 per transaction and $709.19 per recipient, GlaxoSmithKline, LLC.'s Program Year 2024 total comes to $242,144,381.40 across 361,110 transactions and 341,439 physicians and teaching hospitals. In the CMS Open Payments database that is good for rank #13 of 1,925 companies, a top-tier 1.7% share of all industry payments reported nationwide for the year.
The 8-category breakdown below covers general payments only (see our methodology for how research and ownership payments are reported separately). The largest general-payment category is "Compensation for Services Other Than Consulting" at $11.3M, accounting for 42.7% of this company's General Payments and 3,774 transactions.
General Payment Breakdown by Type
"Compensation for Services Other Than Consulting" leads GlaxoSmithKline, LLC.'s 8-category general-payment breakdown at $11.3M, 42.7% of the reported total.
GlaxoSmithKline, LLC. reports 8 general-payment categories - the top three are Compensation for Services Other Than Consulting (42.7%), Food and Beverage (26.1%), and Consulting Fee (22.9%). The remaining 5 categories make up 8.3% of this company's reported general-payment total. That multi-category mix is the kind of profile single-category reporters cannot show.
Category breadth matters here: GlaxoSmithKline, LLC. files across 8 named CMS general-payment types in Program Year 2024, versus manufacturers that report a single dominant category. The chart and table below enumerate every type with an amount above zero for this company.
How GlaxoSmithKline, LLC. divides its payments
How the reported total splits across payment categories
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Compensation for Services Other Than Consulting | $11.3M | 3,774 | 42.7% |
| Food and Beverage | $6.9M | 332,251 | 26.1% |
| Consulting Fee | $6.1M | 1,788 | 22.9% |
| Travel and Lodging | $1.8M | 3,439 | 6.9% |
| Grant | $187.0K | 10 | 0.7% |
| Compensation for Faculty or Speaker (Medical Education) | $102.1K | 9 | 0.4% |
| Space Rental or Facility Fees | $59.4K | 22 | 0.2% |
| Education | $7.9K | 146 | 0.0% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $1,371,970.45 (5.2%) of $26,443,627.44 in this company's General Payments records across 87,620 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for GlaxoSmithKline, LLC.
The five named recipients with the highest reported General Payments from this company
- 1
Cedric James Franklin Rutland II
$387,669.45 across 105 reported transactions
- 2
Harry C Dietz III
$322,704.43 across 1 reported transactions
- 3
Jesse Lyle Goodman
$309,664.88 across 1 reported transactions
- 4
National Jewish Health
$186,000.00 across 3 reported transactions
- 5
Antonio Ramirez Anzueto
$165,931.69 across 107 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as GlaxoSmithKline, LLC.'s, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about GlaxoSmithKline, LLC..
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with GlaxoSmithKline, LLC..
Showing 6 of 1,924 companies with CMS-reported payment data.
BioNTech SE
$204.8M 179 recipients
Compare payment profiles
Takeda Pharmaceuticals U.S.A., Inc.
$199.9M 172,058 recipients
Compare payment profiles
Medtronic, Inc.
$189.9M 342,681 recipients
Compare payment profiles
Boehringer Ingelheim Pharmaceuticals, Inc.
$148.9M 216,716 recipients
Compare payment profiles
Amgen Inc.
$343.0M 474,864 recipients
Compare payment profiles
Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.